Natural Investments LLC Sells 1,295 Shares of Stryker Corporation (NYSE:SYK)

Key Points

• Natural Investments LLC has reduced its stake in Stryker Corporation by 30.5%, selling 1,295 shares and now holding 2,950 shares worth approximately $1,098,000.
• Several institutional investors, including GAMMA Investing LLC, have significantly increased their positions in Stryker, with GAMMA raising its ownership by 43,226.8% to over 2 million shares.
• Stryker reported better-than-expected quarterly earnings of $3.13 EPS, surpassing estimates, with a revenue of $6.02 billion and a year-over-year growth of 11.1%.

Natural Investments LLC lowered its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 30.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,950 shares of the medical technology company's stock after selling 1,295 shares during the quarter. Natural Investments LLC's holdings in Stryker were worth $1,098,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SYK. GAMMA Investing LLC lifted its position in Stryker by 43,226.8% during the first quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock valued at $772,390,000 after buying an additional 2,070,133 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Stryker during the fourth quarter valued at $154,140,000. Northern Trust Corp lifted its position in Stryker by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after buying an additional 420,153 shares during the period. APG Asset Management N.V. lifted its position in Stryker by 1,695.0% during the fourth quarter. APG Asset Management N.V. now owns 370,226 shares of the medical technology company's stock valued at $128,730,000 after buying an additional 349,601 shares during the period. Finally, Voya Investment Management LLC lifted its position in Stryker by 79.2% during the fourth quarter. Voya Investment Management LLC now owns 706,724 shares of the medical technology company's stock valued at $254,412,000 after buying an additional 312,434 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Truist Financial raised their price objective on Stryker from $410.00 to $415.00 and gave the company a "hold" rating in a research report on Monday. Evercore ISI raised their price objective on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Needham & Company LLC lifted their price target on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $430.10.

Stryker Price Performance

NYSE SYK opened at $381.04 on Wednesday. Stryker Corporation has a one year low of $316.01 and a one year high of $406.19. The stock has a 50-day moving average of $387.49 and a 200 day moving average of $380.36. The company has a market capitalization of $145.68 billion, a price-to-earnings ratio of 50.47, a PEG ratio of 2.78 and a beta of 0.91. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same period last year, the company earned $2.81 EPS. Stryker's revenue for the quarter was up 11.1% on a year-over-year basis. On average, sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Monday, June 30th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Monday, June 30th. Stryker's payout ratio is currently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.